Cadila Healthcare has posted satisfactory performance during the first quarter ended June 2014 and its consolidated net profit increased by 23.1 per cent to Rs.240 crore from Rs.195 crore in the corresponding period of last year. Its consolidated net sales moved up by 25.7 per cent to Rs.2020 crore from Rs.1,607 crore. EPS worked out to Rs.11.73 as against Rs.9.53 in the last period.

Its other income declined to Rs.10.41 crore from Rs.12.53 crore. The company reduced its interest burden to Rs.18 crore from Rs.28 crore. Its depreciation charges went up to Rs.67.70 crore from Rs.47.12 crore due to changed the depreciation charge based on the revised remaining useful lives of the assets. Similarly, its taxation provision went up sharply to Rs.52.44 crore from Rs.20.31 crore.

The company's sales in US increased by 88 per cent. It filed 26 additional ANDAs with the US FDA and launched 4 new products in the US. It achieved a growth of 19 per cent with 12 new product launches in the different emerging markets. In the domestic formulations market, it launched 19 new products, including line extensions, of which 6 products were the first to be launched in India.

Its small molecule NCE, Zydpla1 advanced to phase I clinical evaluation in US. Zydpla1 works by blocking the enzyme Dipeptidyl Peptidase-4 (DPP-4) and aims at an overall improvement in the glucose homoeostasis, including reduction in HbA1c and blood sugar levels. The group also made brisk progress in its biologics research programme advancing its pipeline of mABs. The group also initiated global clinical trials for one of the first generation biosimilars, which is currently being marketed in India.